APL93: Timing of CxT and Role of Maintenance

PHASE3CompletedINTERVENTIONAL
Enrollment

576

Participants

Timeline

Start Date

January 31, 1993

Primary Completion Date

December 31, 1998

Study Completion Date

December 31, 1998

Conditions
Leukemia, Promyelocytic, Acute
Interventions
DRUG

ATRA

early introduction of ATRA

DRUG

ATRA and or Chemo as maintenance

patients were randomized both to receive or not receive intermittent ATRA (45 mg/m2/d, 15 days every 3 months) and to receive or not receive continuous CT with 6 mercaptopurine (90 mg/m2/d, orally) and methotrexate (15 mg/m2/wk, orally), according to a 2-by-2 factorial design stratified on the initial induction treatment group

All Listed Sponsors
collaborator

DRC lille, France

UNKNOWN

lead

Groupe d'etude et de travail sur les leucemies aigues promyelocytaires

OTHER

NCT00599937 - APL93: Timing of CxT and Role of Maintenance | Biotech Hunter | Biotech Hunter